ProfileOfResearchers

TÃTULO: SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) plus Ctx versus trastuzumab (T) plus Ctx in patients (pts) with pretreated HER2+metastatic (met) breast cancer (MBC).
AUTORES: Santiago Escriva; Seock Ah Im; Fatima Cardoso; Javier Cortes; Giuseppe Curigliano; William John Gradishar; Mark D Pegram; Gail Lynn Shaw Wright; Christelle Levy; Michelino De laurentiis; Jean Marc Ferrero; Shakeela Wazeen Bahadur; Sung Bae Kim; Katarina Petrakova; David A Riseberg; Denise A Yardley; Sutton Edlich; Sam Hong; Edwin P Rock; Hope S Rugo;
PUBLICAÇÃO: 2020, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 38, NÚMERO: 15

INDEXADO EM:

WOS

TÃTULO: SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) plus chemotherapy (C) versus trastuzumab (T) plus C in patients (pts) with HER2+metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).
AUTORES: Hope S Rugo; Seock Ah Im; Gail Lynn Shaw Wright; Santiago Escriva de Romani; Michelino DeLaurentiis; Javier Cortes; Shakeela Wazeen Bahadur; Barbara B Haley; Raul H Oyola; David A Riseberg; Antonino Musolino; Fatima Cardoso; Giuseppe Curigliano; Peter A Kaufman; Mark D Pegram; Sutton Edlich; Sam Hong; Edwin P Rock; William John Gradishar;
PUBLICAÇÃO: 2019, FONTE: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 37, NÚMERO: 15

INDEXADO EM:

WOS

TÃTULO: Settings-based efficacy comparison of trastuzumab biosimilars in breast cancer: A systematic literature review
AUTORES: Rugo, HS; Curigliano, G; Cardoso, F; Gradishar, WJ; Pegram, M; Barrios, CHH; Cortes Castan, JC; Pennella, E; Muniz, R;
PUBLICAÇÃO: 2018, FONTE: 43rd ESMO Congress (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 29

INDEXADO EM:

WOS

TÃTULO: SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+metastatic breast cancer
AUTORES: Rugo, HS; Pegram, MD; Gradishar, WJ; Cortes, J; Curigliano, G; Hong, S; Wigginton, JM; Lechleider, RJ; Cardoso, F;
PUBLICAÇÃO: 2017, FONTE: San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 77

INDEXADO EM:

WOS

TÃTULO: A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer Full Text
AUTORES: Hope S Rugo; Olivier Tredan; Jungsil Ro; Serafin M Morales; Mario Campone; Antonino Musolino; Noemia Afonso; Marta Ferreira; Kyong Hwa Park; Javier Cortes; Antoinette R Tan; Joanne L Blum; Lamar Eaton; Christine K Gause; Zhen Wang; Ellie Im; David J Mauro; Mary Beth Jones; Andrew Denker; Jose Baselga;
PUBLICAÇÃO: 2017, FONTE: BREAST CANCER RESEARCH AND TREATMENT, VOLUME: 165, NÚMERO: 3

INDEXADO EM:

WOS

TÃTULO: Variation in the use of mastectomy (MAST) in women with small node negative breast cancer (BC) treated at US academic institutions
AUTORES: Ines Vaz Luis; Melissa E Hughes; Angel Cronin; Hope S Rugo; Stephen B Edge; Beverly Moy; Richard Theriault; Michael J Hassett; Eric P Winer; Nancy U Lin;
PUBLICAÇÃO: 2015, FONTE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, NÚMERO: 9

INDEXADO EM:

WOS

TÃTULO: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer
AUTORES: Hope S Rugo; Olivier Tredan; Jungsil Ro; Serafin Morales; Antonino Musolino; Noemia Afonso; Marta Ferreira; Kyong Hwa Park; Javier Cortes; Antoinette R Tan; Joanne L Blum; Lamar Eaton; Christine K Gause; Adelle (Zhen) Wang; Ellie Im; David J Mauro; Jose Baselga;
PUBLICAÇÃO: 2015, FONTE: 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 75, NÚMERO: 9

INDEXADO EM:

WOS